Passage Bio Inc (PASG)

$0.60 0.00 (N/A)
Market Cap 37.06M
Revenue (ttm) 0.00
Net Income (ttm) -102.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 230,100
Avg Vol 883,474
Day's Range N/A - N/A
Shares Out 61.77M
Stochastic %K 12%
Beta 1.54
Analysts Strong Sell
Price Target $7.00

Latest News on PASG

Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates

Jan 10, 2025, 7:00 AM EST - 7 days ago

Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates

Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference

Nov 6, 2024, 7:00 AM EST - 2 months ago

Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference

Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference

Oct 24, 2024, 7:00 AM EDT - 3 months ago

Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference

Passage Bio to Present at Chardan's 8th Annual Genetic Medicines Conference

Sep 23, 2024, 7:00 AM EDT - 4 months ago

Passage Bio to Present at Chardan's 8th Annual Genetic Medicines Conference

Passage Bio Welcomes Tom Kassberg to Board of Directors

Sep 10, 2024, 7:52 AM EDT - 4 months ago

Passage Bio Welcomes Tom Kassberg to Board of Directors

Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 30, 2024, 7:00 AM EDT - 5 months ago

Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference

Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights

Aug 8, 2024, 7:00 AM EDT - 5 months ago

Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights

Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration

Aug 1, 2024, 7:00 AM EDT - 6 months ago

Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration

Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients

Jul 16, 2024, 7:00 AM EDT - 6 months ago

Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients

Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference

Jun 5, 2024, 7:30 AM EDT - 8 months ago

Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference

Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award

May 21, 2024, 8:00 AM EDT - 8 months ago

Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award

Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights

May 14, 2024, 7:00 AM EDT - 8 months ago

Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights

Passage Bio to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Apr 22, 2024, 7:00 AM EDT - 9 months ago

Passage Bio to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights

Mar 4, 2024, 7:00 AM EST - 11 months ago

Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights

Passage Bio to Participate in Upcoming Investor Conferences

Feb 27, 2024, 7:00 AM EST - 11 months ago

Passage Bio to Participate in Upcoming Investor Conferences

Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 31, 2024, 7:30 AM EST - 1 year ago

Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

Dec 20, 2023, 7:00 AM EST - 1 year ago

Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Nov 17, 2023, 4:30 PM EST - 1 year ago

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

Nov 13, 2023, 7:00 AM EST - 1 year ago

Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

Passage Bio to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference

Oct 30, 2023, 7:00 AM EDT - 1 year ago

Passage Bio to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 20, 2023, 4:30 PM EDT - 1 year ago

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Passage Bio to Present at Chardan's 7th Annual Genetic Medicines Conference

Sep 25, 2023, 7:00 AM EDT - 1 year ago

Passage Bio to Present at Chardan's 7th Annual Genetic Medicines Conference

Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights

Aug 7, 2023, 7:15 AM EDT - 1 year ago

Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights

Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study

Aug 7, 2023, 7:00 AM EDT - 1 year ago

Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study

Passage Bio to Participate in Upcoming Investor Conferences

Aug 1, 2023, 7:00 AM EDT - 1 year ago

Passage Bio to Participate in Upcoming Investor Conferences

Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors

Jul 31, 2023, 7:00 AM EDT - 1 year ago

Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors

Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference

Jun 5, 2023, 7:00 AM EDT - 1 year ago

Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference

Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights

May 11, 2023, 7:00 AM EDT - 1 year ago

Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 21, 2023, 4:01 PM EDT - 1 year ago

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Passage Bio to Present at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Apr 17, 2023, 7:00 AM EDT - 1 year ago

Passage Bio to Present at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days

Mar 27, 2023, 7:00 AM EDT - 1 year ago

Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days

Passage Bio, Inc. (PASG) Q4 2022 Earnings Call Transcript

Mar 6, 2023, 1:07 PM EST - 2 years ago

Passage Bio, Inc. (PASG) Q4 2022 Earnings Call Transcript

Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights

Mar 6, 2023, 7:00 AM EST - 2 years ago

Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights

Passage Bio Undervalued On Price, Long-Term Gene Therapy Prospects

Feb 28, 2023, 11:39 PM EST - 2 years ago

Passage Bio Undervalued On Price, Long-Term Gene Therapy Prospects

Passage Bio to Present at Cowen 43rd Annual Health Care Conference

Feb 28, 2023, 7:00 AM EST - 2 years ago

Passage Bio to Present at Cowen 43rd Annual Health Care Conference

Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023

Feb 27, 2023, 7:00 AM EST - 2 years ago

Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023

Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023

Feb 24, 2023, 7:00 AM EST - 2 years ago

Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023

Passage Bio to Present Updated Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023

Feb 15, 2023, 7:00 AM EST - 2 years ago

Passage Bio to Present Updated Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023

Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study

Dec 14, 2022, 7:00 AM EST - 2 years ago

Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study

Passage Bio, Inc. (PASG) Q3 2022 Earnings Call Transcript

Nov 10, 2022, 10:26 AM EST - 2 years ago

Passage Bio, Inc. (PASG) Q3 2022 Earnings Call Transcript

Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates

Nov 10, 2022, 7:00 AM EST - 2 years ago

Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates

Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022

Nov 3, 2022, 7:30 AM EDT - 2 years ago

Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022

Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer

Oct 10, 2022, 7:00 AM EDT - 2 years ago

Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer

Passage Bio to Present at Chardan's 6th Annual Genetic Medicines Conference

Sep 26, 2022, 7:00 AM EDT - 2 years ago

Passage Bio to Present at Chardan's 6th Annual Genetic Medicines Conference

Newman Ferrara LLP Announces Corporate Governance Investigations of Passage Bio, Inc. (PASG)

Sep 7, 2022, 4:40 PM EDT - 2 years ago

Newman Ferrara LLP Announces Corporate Governance Investigations of Passage Bio, Inc. (PASG)

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Aug 19, 2022, 4:01 PM EDT - 2 years ago

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations

Aug 11, 2022, 7:00 AM EDT - 2 years ago

Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations

Passage Bio, Inc. (PASG) CEO Edgar Cale on Q2 2022 Results - Earnings Call Transcript

Aug 6, 2022, 10:50 AM EDT - 2 years ago

Passage Bio, Inc. (PASG) CEO Edgar Cale on Q2 2022 Results - Earnings Call Transcript

Passage Bio to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference

Aug 5, 2022, 7:00 AM EDT - 2 years ago

Passage Bio to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference

Passage Bio Reports Second Quarter 2022 Financial Results and Provides Recent Business Highlights

Aug 4, 2022, 7:00 AM EDT - 2 years ago

Passage Bio Reports Second Quarter 2022 Financial Results and Provides Recent Business Highlights